Episodi
-
Daniel Mora-Brito joins Lucy Chard to discuss the health landscape in the African continent, covering some of the greatest threats seen there over the years and that are still impacting people’s lives on a daily basis, helping to drive home the importance of improved, localised healthcare in the continent. Lucy and Daniel talk about the economic factors that underpin a lot of the transformations across the region, from the perspective of those on home turf and the companies from different regions looking to invest and expand into this space. Daniel mentions the different actors in the region and what expanding capacities in Africa will mean for patient access in a rapidly expanding population.
-
This podcast episode aims to explain the importance and intricacies of developing excipients and then goes into more depth regarding the excipient market, how this differs globally, what tactics different companies are now using to gain ground and push the field forward to be able to develop more innovative drug delivery systems.
Digital Editor Lucy Chard is joined by Nick DiFranco, MEM, the Global Market Manager for Novel Pharmaceutical Excipients at Lubrizol Life Science.
Lubrizol is a pioneer in the novel excipient development space so DiFranco can give a deep level of insight into the field as it stands, some of the innovative products they’re developing at Lubrizol, and the trends to look out for the in future.
-
Episodi mancanti?
-
Welcome to the last episode of 2023! Digital Editor Lucy Chard is joined by her team in a special retrospective episode to close out the year. Guests Vivian Xie, Editor for CPHI Online and Tara Dougal, Content Director for Pharma, discuss their highlights from the year; diversity, sustainability, and the CPHI Barcelona event cropping up as top features. The Women in Pharma series that Vivian has worked on for the past year has been a resounding success, some of our most impactful content on CPHI Online, which, as arguably some of our most important content we are so pleased to see that reflected with our audience. We also cover sustainability, drug approvals, Alzheimer's research, mRNA oncology vaccines, and digital marketing for pharma companies.
To see more about everything we mentioned in the podcast, see the links below:
Women in Pharma Interviews
Women in Pharma: Advancing gender diversity & healthcare equality - https://www.cphi-online.com/women-in-pharma-advancing-gender-diversity-news121441.html
Women in Pharma: Empowering yourself and other women in pharma - https://www.cphi-online.com/women-in-pharma-empowering-yourself-and-other-news122294.html
Sustainability
CPHI Sustainability Trend Report 2023: Towards a Greener Future - https://www.cphi-online.com/cphi-sustainability-trend-report-2023-towards-a-news121332.html
CPHI Podcast Series: An insight into the Chief Sustainability Officer - https://www.cphi-online.com/cphi-podcast-series-an-insight-into-the-chief-news120741.html
CPHI Podcast Series: Sustainable Strategies in the Pharmaceutical Packaging Industry - https://www.cphi-online.com/cphi-podcast-series-sustainable-strategies-in-the-news119779.html
Top Content
Your Prescription for Marketing Success: Digital Pharma Marketing Toolkit – Free eBook - https://www.cphi-online.com/your-prescription-for-marketing-success-digital-news121086.html
10 Major Drug Approvals So Far in 2023 - https://www.cphi-online.com/10-major-drug-approvals-so-far-in-2023-news121294.html
CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond - https://www.cphi-online.com/cphi-podcast-series-exploring-neurological-news122273.html
The CPO Starter Pack: Why and When to Bring in a Contract Packaging Partner - https://www.cphi-online.com/the-cpo-starter-pack-why-and-when-to-bring-in-a-news120889.html
Ashwagandha and Herbal Medicines: Pharma’s Next Big Opportunity -
-
In this special post-CPHI Barcelona episode, host Lucy Chard speaks to Matthew Wise from CCD Partners about the Start-up Market held at the event. In this podcast they speak about the event, which for the first time held a specific area for Start-up companies, something that is particularly applicable to the Catalan region as a leading area for innovation in pharma and healthcare, they also talk about discuss what this start-up market means for the companies, as well as for investors and potential partners, and for the future of pharma innovation.
-
This episode covers the recent changes in legislature around drug pricing in the USA, and what this means for the global pharma market, as well as the impact it will have on the US population in terms of access to medicine. The price negotiations with Medicare are targeting medications used in the treatment of many chronic diseases such as cardiovascular disease and diabetes. We will take a look at what this means for people with chronic disease, and conversely the impact on the individual pharma companies and then more widely, on innovation in the industry.
-
Digital Editor for CPHI Online, Lucy Chard, is joined by Alan Palmer of Elixa MediScience to talk about neurological disorders including Alzheimer’s disease and everything that is encompassed under this terminology, spanning the history of disease, the social impacts, the different modalities and developments in therapeutics, and what the future of research into care in this field holds.
-
Digital Editor Lucy Chard speaks with Bill Whitford of DPS Groupabout the integration of AI in healthcare. Bill gives context to the use of AI in different aspects of medicine and drug discovery, including how it can help revamp drug repurposing strategies and save time when searching for drug targets. We also see the implications the technology could have socially, by helping to eliminate bias in clinical trials, and the prospect of how far AI could go.
-
In this episode of the CPHI Podcast Series, Digital Editor Lucy Chard is joined by Sandra Sánchez y Oldenahrey, the President and CEO of PharmaAdvice. Sandra has 35 years of experience in the Life Sciences industry, working with giants in the pharma field throughout Latin America, Canada, and parts of Asia. In this interview, Sandra discusses the practicalities of nearshoring, the benefits it gives to companies as well as individuals, and the effects it has socially and economically on a global scale.
-
Gil Roth, President of the Pharma & Biopharma Outsourcing Association, delves into the most exciting aspects of outsourcing and manufacturing in this interview, including some of the biggest areas of innovation and technology, such as cell and gene therapeutics. We also get an update on the industry as a whole since the COVID-19 pandemic and how companies are adapting to changes in the market and regional trends.
-
In this episode from the CPHI Podcast Series Louise Duffy and Campbell Bunce from Abzena speak to Digital Editor Lucy Chard, using their cumulative knowledge to give an overview of the drug development and manufacturing processes, demonstrating all of the aspects that go into such an undertaking as making a new drug for a patient population.
They highlight some of the key areas that teams have to work on, the detailed analysis that has to take place at each stage, as well as within the wider context with regulations to consider, and finally they highlight some of the key areas for innovation and for expanding knowledge in the field.
-
In this episode Digital Editor Lucy Chard finds out more about being the Chief Sustainability Officer in the pharmaceutical industry from Nic Hunt, Global Head of Sustainability at Nelipak Healthcare Packaging.
In the podcast we discuss what it means to be in the role of a Chief Sustainability Officer, how the role is set to develop along with more established sustainability teams. The role they provide is so integral to the overall health of a pharma company, the pharma supply chain and subsequently the health of the planet. Hunt's optimism about the industry making real changes to how they work and meeting goals such as Net Zero really comes across, with the outlook for the future of sustainability in pharma a bright one.
-
The podcast focused on the 30 year anniversary of Ursatec in the provision of preservative-free pharmaceuticals, medical devices and cosmetics. We took a look through the Ursatec portfolio, the importance of safety and sustainability in their products, and what the future holds for the company.
-
As part of celebrating International Women’s Day on the 8th March 2023, we wanted to highlight the importance of supporting women’s health. Historically, women’s medicine, in relation to diseases, and sexual and reproductive rights, has been chronically overlooked in the wider field. We hope to use this podcast with special guest Dr Charlotte Fairweather, to open up a wider conversation about educating and empowering women so they can access the healthcare they need.
-
Rare disease is an often overlooked field of medicine, but one which is rapidly gaining ground, which is certainly a good thing as rare diseases affect around 300 million people globally.
By their nature, rare diseases are incredibly difficult to research and develop medicines for, but this just makes it all the more urgent to fulfil this unmet need for rare disease patients.
In this podcast I am joined by Rachel Smith; Rachel is the Executive Director, Global Head of Rare Diseases at Parexel. Rachel brings more than a decade of experience in every development phase of rare disease and cell and gene therapy clinical trials to her work with Parexel’s rare disease clients.
Previously, she served as Vice President of Clinical Operations, Portfolio Director of Rare Disease, and Global Head of the Cell & Gene Center of Excellence at Veristat LLC. She led programs in ADA-SCID, Canavan disease, congenital adrenal hyperplasia, Fabry disease, Gaucher disease, metachromatic leukodystrophy, and Wiskott-Aldrich Syndrome. Rachel has expertise in clinical development strategy, novel and adaptive trial design, decentralized trials, and other creative solutions for rare disease products with a non-classical route to market.
-
Sustainability in pharma is now gaining the recognition it deserves, quickly becoming one of the biggest priorities for pharma companies across the spectrum.
Upgrading this Packaging in pharma comes in all shapes and sizes – whether we are talking about replacing single use plastics in manufacturing, or waste management at the end of the commercial chain.
Today we will be talking about sustainability in the pharmaceutical packaging industry, how it can be more ingrained and the impact it will have, with an expert from a leading European packaging company, Adelphe. Félicie Pachot is the Health Marketing Manager at Adelphe and she goes into the model Adelphe uses to support sustainable practices through recycling, reduction of waste, and resue.
-
In this latest episode from the CPHI Podcast Series, Digital Editor Lucy Chard speaks to Sanjay Sharma, Global Head of Manufacturing, from Dr Reddy’s. Sanjay has over 26 years of experience in roles encompassing sales, the supply chain, and technical operations.
Pharma 4.0 is the upgrading of the pharma industry to a more digitalised state, including automation of processes and greater system integration. This has a wealth of advantages, such as leading to greater compliance and quality control in the manufacturing process. Pharma 4.0 also leads to increasing the sustainability of many aspects of the pharmaceutical chain. Dr Reddy’s is a leading pharmaceutical company and is at the forefront of adopting industry 4.0 into their everyday systems.
Dr Reddy’s largest manufacturing facility in Bachupally, Hyderabad, India, recently joined the Global Lighthouse Network of the World Economic Forum, a network of over 100 manufacturing companies committed to developing and leading the progression into Industry 4.0 technologies.
This commitment from Dr Reddy’s will help to reduce manufacturing costs, production lead time, and energy consumption, as well as increasing the quality assurance throughout the manufacturing process.
-
The pharmaceutical industry is brimming with innovation – from biologics such as cell and gene therapies to COVID-19 treatments and precision oncology drugs. And as pharmaceuticals grow more advanced, so too must the drug delivery and packaging solutions that get them safely from the manufacturer to the patient.
This is a competitive arena and among all the companies operating in this space, startups are generally seen as the drivers of innovation, often taking high-risk approaches and doing business with greater agility.
In this episode, CPHI is joined by Gareth Pearce, founder of Pacifi Ltd, a startup that modifies glass vials with laser technology to create DuoVIAL, an innovative lyophilized drug delivery solution. Gareth takes us through his company’s journey, explains his long-term vision and speaks more broadly about the role events can play in a startup’s path to success.
Listen to the full episode now.
-
An outbreak of zoonotic disease can have devastating economic and social consequences, as evidenced by the COVID-19 pandemic and increasing concern over monkeypox. Defined as a disease that has transitioned from a vertebrate animal to humans, zoonoses account for about 60% of known infectious diseases and 75% of new or emerging infectious diseases.
So, what can be done to limit the spread of these diseases and prevent the next pandemic?
In the latest episode in the CPHI Podcast Series, we hear from two companies – Chipsafer and SoundTalks - whose products use data analytics and AI to identify diseases in animals at the earliest indication. Chipsafer is a patented platform that detects and tracks anomalies in livestock behaviour, giving farmers earlier warning when disease breaks out in the herd. Joining us to break down how the platform works is Chipsafer’s founder and CEO, Victoria Alonsoperez. Similarly, SoundTalks is a company that provides real-time health monitoring in pig herds, using microphones and sound analytics to detect possible outbreaks of respiratory disease. SoundTalks’ founder Dries Berckmans joins us to discuss.
-
Excipients are essential to the formulation of drug products, but their importance in supporting innovative drug development is often underestimated. According to the International Pharmaceutical Excipients Council (IPEC), drugs that have yet to be developed may need more excipients than are currently available to us, and many new treatments are unlikely to succeed without novel excipients. In short – innovation in drug development requires innovation in excipient manufacturing.
However, the lack of an independent regulatory pathway for novel excipients has historically created barriers to their use and discouraged innovation in the excipients space. In this episode Nigel Langley, Chair of IPEC – Americas and Global Technology Director at BASF Corporation, joins us to discuss developments in the novel excipients arena, as well as the pilot review program launched by the FDA last year.
-
The supplements market is on the rise, with products like vitamins, herbal drinks, and protein powders found in more household cupboards than ever before. The increasing popularity of supplements has coincided with the rise of wellness culture and increasing interest in preventative healthcare, spurred by the COVID-19 pandemic. In fact, the market was declining before emergence of the coronavirus reignited global sales.
Supplements can be an excellent way to cover deficiencies not addressed by food intake, but the wide range of products available in health food shops, pharmacies and supermarkets can be overwhelming for consumers. And while market growth is expected to continue, products such as herbal supplements and CBD continue to face regulatory issues and scrutiny over the soundness of their health claims.
To discuss the latest trends in the supplements space, we’re joined this month by David Ridley, Senior Editor at HBW Insight and host of Over the Counter podcast. He tells us which products surged in popularity during the pandemic, discusses the rise of self-care, and gives an overview of the regulatory environment in Europe.
- Mostra di più